674 related articles for article (PubMed ID: 29465470)
1. Opioid addiction, diversion, and abuse in chronic and cancer pain.
Kata V; Novitch MB; Jones MR; Anyama BO; Helander EM; Kaye AD
Curr Opin Support Palliat Care; 2018 Jun; 12(2):124-130. PubMed ID: 29465470
[TBL] [Abstract][Full Text] [Related]
2. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
3. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
4. Opioids with abuse-deterrent properties: A regulatory and technological overview.
Haddox JD
J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
[TBL] [Abstract][Full Text] [Related]
5. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
6. Use and Misuse of Opioids in Chronic Pain.
Volkow N; Benveniste H; McLellan AT
Annu Rev Med; 2018 Jan; 69():451-465. PubMed ID: 29029586
[TBL] [Abstract][Full Text] [Related]
7. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
8. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting.
Brown J; Setnik B; Lee K; Wase L; Roland CL; Cleveland JM; Siegel S; Katz N
J Opioid Manag; 2011; 7(6):467-83. PubMed ID: 22320029
[TBL] [Abstract][Full Text] [Related]
9. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
Hale ME; Moe D; Bond M; Gasior M; Malamut R
Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830
[TBL] [Abstract][Full Text] [Related]
10. Challenges and concerns of persistent opioid use in cancer patients.
Manchikanti L; Manchikanti KN; Kaye AD; Kaye AM; Hirsch JA
Expert Rev Anticancer Ther; 2018 Jul; 18(7):705-718. PubMed ID: 29739242
[TBL] [Abstract][Full Text] [Related]
11. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
Gasior M; Bond M; Malamut R
Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
[TBL] [Abstract][Full Text] [Related]
12. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
Webster LR; Markman J; Cone EJ; Niebler G
Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
[TBL] [Abstract][Full Text] [Related]
13. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
Manchikanti L; Kaye AM; Knezevic NN; McAnally H; Slavin K; Trescot AM; Blank S; Pampati V; Abdi S; Grider JS; Kaye AD; Manchikanti KN; Cordner H; Gharibo CG; Harned ME; Albers SL; Atluri S; Aydin SM; Bakshi S; Barkin RL; Benyamin RM; Boswell MV; Buenaventura RM; Calodney AK; Cedeno DL; Datta S; Deer TR; Fellows B; Galan V; Grami V; Hansen H; Helm Ii S; Justiz R; Koyyalagunta D; Malla Y; Navani A; Nouri KH; Pasupuleti R; Sehgal N; Silverman SM; Simopoulos TT; Singh V; Solanki DR; Staats PS; Vallejo R; Wargo BW; Watanabe A; Hirsch JA
Pain Physician; 2017 Feb; 20(2S):S3-S92. PubMed ID: 28226332
[TBL] [Abstract][Full Text] [Related]
14. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2).
Kaye AD; Jones MR; Kaye AM; Ripoll JG; Jones DE; Galan V; Beakley BD; Calixto F; Bolden JL; Urman RD; Manchikanti L
Pain Physician; 2017 Feb; 20(2S):S111-S133. PubMed ID: 28226334
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients.
Coplan PM; Cepeda MS; Petronis KR; DeVeaugh-Geiss A; Barsdorf AI; Kern DM; Fanelli R
Postgrad Med; 2020 Jan; 132(1):44-51. PubMed ID: 31721609
[No Abstract] [Full Text] [Related]
16. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
Vosburg SK; Severtson SG; Dart RC; Cicero TJ; Kurtz SP; Parrino MW; Green JL
J Pain; 2018 Apr; 19(4):439-453. PubMed ID: 29224919
[TBL] [Abstract][Full Text] [Related]
17. Managing Chronic Pain in Cancer Survivors Prescribed Long-Term Opioid Therapy: A National Survey of Ambulatory Palliative Care Providers.
Merlin JS; Patel K; Thompson N; Kapo J; Keefe F; Liebschutz J; Paice J; Somers T; Starrels J; Childers J; Schenker Y; Ritchie CS
J Pain Symptom Manage; 2019 Jan; 57(1):20-27. PubMed ID: 30342243
[TBL] [Abstract][Full Text] [Related]
18. Trends in opioid analgesic abuse and mortality in the United States.
Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
[TBL] [Abstract][Full Text] [Related]
19. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
20. Characterization of prescription opioid abuse in the United States: focus on route of administration.
Kirsh K; Peppin J; Coleman J
J Pain Palliat Care Pharmacother; 2012 Dec; 26(4):348-61. PubMed ID: 23675595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
